Intrinsic Value of S&P & Nasdaq Contact Us

Exactus, Inc. EXDI OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
17/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Exactus, Inc. (EXDI) generated $-3.86M in operating cash flow for quarter ending 2021-09-30. After capital expenditures of $0.00, free cash flow was $-3.86M.

Free cash flow margin was -655.8% of revenue. Cash conversion ratio was 1.22x, indicating earnings are backed by cash.

Criteria supported by this page:

  • HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
  • MOAT (15/100, Fail) — limited free cash flow weakens the competitive position
  • INCOME (10/100) — Cash conversion ratio was 1.22x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 16/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
17/100
SG Score
View full scorecard →
VALUE
N/A
No coverage
FUTURE
N/A
No coverage
PAST
0/100
→ Income
HEALTH
0/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
15/100
Proven by this page
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income
Exactus, Inc. Cash Flow History
Metric TTM Q3 FY2021 Q2 FY2021 Q1 FY2021 Q4 FY2020
Operating Cash Flow $-2.52M$-3.86M$1.49M$-25.42K$-129.26K
Capital Expenditure $0.00$0.00$0.00$0.00$0.00
Free Cash Flow $-2.52M$-3.86M$1.49M$-25.42K$-129.26K
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message